Education
About Us
Working with TipRanks
Follow Us
PhoenixBio Co., Ltd. (JP:6190)
:6190
6190 Stock Chart & Stats
¥484.00
¥9.00(2.79%)
At close: 4:00 PM EST
¥484.00
¥9.00(2.79%)
Day’s Range― - ―
52-Week Range¥252.00 - ¥724.00
Previous CloseN/A
Volume3.50K
Average Volume (3M)360.67K
Market Cap
¥1.80B
Enterprise Value¥1.41B
Total Cash (Recent Filing)¥1.04B
Total Debt (Recent Filing)¥503.59M
Price to Earnings (P/E)6.1
Beta0.54
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)19.91
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.97
P/FCF Ratio-15.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Humanized Model PlatformPhoenixBio's PXB humanized-mouse platform is a durable competitive asset: it supplies specialized preclinical data critical to drug metabolism and safety programs. This creates recurring fee-for-service and product revenue, high switching costs for customers, and defensible niche positioning over months to years.
Historically Strong Gross MarginsConsistently strong gross margins on core hepatocyte/model products indicate favorable unit economics from proprietary biological materials and specialized services. Such structural margin strength supports pricing power and long-term reinvestment capacity if operational issues are resolved.
Balance Sheet Equity StrengthA healthy equity ratio and moderate leverage provide financial resilience against industry cyclicality and reduce refinancing risk. This balance-sheet stability preserves capacity to fund platform maintenance, regulatory compliance, or selective investments without immediate reliance on dilutive capital.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flow constrain PhoenixBio's ability to internally fund R&D, capacity expansion, and platform upkeep. Over 2-6 months this increases reliance on external financing or cost reductions, which can slow product development and service throughput vital to customers.
Negative Operating ProfitabilityOngoing negative EBIT/EBITDA and net margins reflect structural operating shortfalls. Sustained unprofitability undermines reinvestment potential and may force pricing, scope, or staffing changes that harm service quality and competitive positioning in specialized preclinical testing markets.
Declining Revenues And Asset BaseA contraction in revenue and total assets signals reduced scale and potentially lower customer demand or utilization of the platform. This erosion of scale limits operating leverage, weakens long-term investment capacity, and raises the risk that competitors could capture share of specialized contract work.
6190 FAQ
What was PhoenixBio Co., Ltd.’s price range in the past 12 months?
PhoenixBio Co., Ltd. lowest stock price was ¥252.00 and its highest was ¥724.00 in the past 12 months.
What is PhoenixBio Co., Ltd.’s market cap?
PhoenixBio Co., Ltd.’s market cap is ¥1.80B.
When is PhoenixBio Co., Ltd.’s upcoming earnings report date?
PhoenixBio Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 71 days.
How were PhoenixBio Co., Ltd.’s earnings last quarter?
PhoenixBio Co., Ltd. released its earnings results on Feb 13, 2026. The company reported ¥19.91 earnings per share for the quarter, beating the consensus estimate of N/A by ¥19.91.
Is PhoenixBio Co., Ltd. overvalued?
According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued.
Does PhoenixBio Co., Ltd. pay dividends?
PhoenixBio Co., Ltd. does not currently pay dividends.
What is PhoenixBio Co., Ltd.’s EPS estimate?
PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhoenixBio Co., Ltd. have?
PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.
What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?
PhoenixBio Co., Ltd. reported an EPS of ¥19.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.112%.
Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Technical Analysis
Trans Genic Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―